SMMT NASDAQ
Summit Therapeutics Inc.
1W: +7.4%
1M: +14.8%
3M: +5.2%
YTD: -4.3%
1Y: -18.2%
3Y: +772.9%
5Y: +221.1%
$16.75
+0.07 (+0.39%)
Weekly Expected Move ±7.4%
$14
$16
$17
$18
$19
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.56
Bullish
5 bullish
3 neutral
0 bearish
Articles (7d)
8
Daily Sentiment (7 Days)
Articles (100)
AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo
High-Stakes October has these Biotechs Entering Crucial Stretch
Summit Shares Jump on $2B Strategic Investment From AstraZeneca
At a glance: stocks gapping up premarket
Biggest stock movers Tuesday: SMMT, NVTS, and more
Analysts back AstraZeneca's $2B Summit Therapeutics investment as stock gains
Summit Therapeutics rises after AstraZeneca commits $2B investment
Summit Therapeutics Jumps on $2 Billion AstraZeneca Investment
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Engineers Gate Manager LP Makes New Investment in Summit Therapeutics PLC $SMMT
At a glance: stocks gapping up premarket
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
Hsbc Holdings PLC Purchases Shares of 120,560 Summit Therapeutics PLC $SMMT
Bank of New York Mellon Corp Takes $6.28 Million Position in Summit Therapeutics PLC $SMMT
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Why Is Summit Therapeutics Stock Soaring Today? - Summit Therapeutics (NASDAQ:SMMT) - Benzinga
Why is Summit Therapeutics stock surging today? - Investing.com
Summit Therapeutics stock rises on positive survival data By Investing.com - Investing.com Australia
November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet - Seeking Alpha
Summit Therapeutics (SMMT) Gains on Positive Phase III Trial Res - GuruFocus
Summit Therapeutics in focus as its lung cancer drug shows survival benefit
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
Ten healthcare stocks leading in year-over-year CapEx growth
Highest and lowest quant-rated healthcare stocks above $10B cap after earnings season
Cantor Fitzgerald reiterates Summit Therapeutics stock rating - Investing.com
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Summit Therapeutics (SMMT) Stock Climbed, So What Is Behind The Move? - Yahoo Finance
Summit Therapeutics (SMMT) Stock Climbed, So What Is Behind The Move?
Summit Therapeutics (SMMT) Published Phase III HARMONi Results In The Lancet Oncology
Summit Therapeutics (SMMT) Is Up 8.5% After New Phase III Biliary Cancer Data For Ivonescimab
Summit’s Global Lung Cancer Trials Gain Credibility After Akeso’s Phase 3 Data, Says Guggenheim
Summit Therapeutics shares rise after partner reports positive Phase III cancer trial results
Summit rises as lead drug from Akeso outperforms Astra’s Imfinzi in late-stage trial
Akeso logs Phase III success in second tumour type for ivonescimab
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
Summit Therapeutics Shares Rise After Bernstein SocGen Upgrade
GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity
GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus
SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data - Stocktwits
$SMMT stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
Summit outlines November 14 FDA PDUFA date for ivonescimab BLA while planning HARMONi-3 PFS in 2H 2026
Summit Therapeutics says cash crunch could impact its ability to continue
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
Summit Therapeutics (SMMT) Stock Looks Stretched On Fresh Lung Cancer Data - Yahoo Finance
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal
$SMMT stock is down 3% today. Here's what we see in our data. - Quiver Quantitative
BioNTech ($BNTX) is arguably the most undervalued stock in the biotech sector today and i dont understand why
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
SMMT Forecast — Price Target — Prediction for 2027 - TradingView
Welltower’s Tim McHugh tops CFO pay rankings with $167M package in 2025
Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing - Yahoo Finance
Summit rebounds after nearly $50M insider purchase
Oil Jumps On Iran Strikes, Nasdaq 100 Falls On Hot Inflation: Stock Market Today
Super Micro Computer, Summit Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Why Is SMMT Stock Tumbling Today? - Stocktwits
Summit Therapeutics files for $500M common stock offering; shares slide over 9%
12 Health Care Stocks Moving In Tuesday's After-Market Session
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy
S&P 500 Halts Gains As Oil Jumps 8% On Iran Ceasefire Standoff: Stock Market Today
What's Going On With Summit Therapeutics Stock On Monday?
Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet
Very confused by $SMMT
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet - Yahoo Finance
Why Is SMMT Stock Surging Over 10% In Overnight Trading? - Stocktwits
This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced
SMMT - Summit Therapeutics Inc Stock Price and Quote - Finviz
Dow Jones Hits Record Highs, DELL Jumps 15%: Stock Market Today
Here's Why You Should Add SMMT Stock to Your Portfolio Now
Why Summit Therapeutics Stock Is Climbing Again - TipRanks
Cancer Stocks That Are Advancing the Future of Oncology Care
Summit Therapeutics Inc. (SMMT) Stock Analysis: Healthcare Innovator with Potential 74% Upside - DirectorsTalk Interviews
(SMMT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Look At Summit Therapeutics (SMMT) Valuation After HARMONi-3 Trial Risk Highlighted By Analyst Commentary
Russell 1000 Is Hiding Some Big AI Winners
H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT)
H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT)
SMMT Stock Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback - Yahoo Finance
Roblox, Spotify, And Robinhood Are Among Top 10 Large-Cap Losers Last Week (April 27-May 1): Are The Others In Your Portfolio?
Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider Losses - Has The Bull Case Changed? - simplywall.st